

February 12, 2025

To,

| | |
|---|---|
| General Manager, Listing Department, Bombay Stock Exchange Limited, P.J. Towers, Dalal Street, Mumbai – 400 001 Company code: 533333 | The Manager, Listing & Compliance Department The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai - 400051 Company code: FCL |
|---|---|

Subject: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, we wish to inform you that the meeting of the Board of Directors of the company held on Wednesday, February 12, 2025, which commenced at **5.00 PM** and concluded at **7.00 PM** has *inter-alia* considered and approved the following matters;

1. The Unaudited Standalone and Consolidated Financial Results of the Company and the Limited Review Reports of the Statutory Auditors thereon for the quarter and nine months ended December 31, 2024.

We enclose a copy of Standalone and Consolidated Unaudited Financial Results along with the Limited Review Report of the Statutory Auditors thereon for the quarter and nine months ended 31st December 2024.

2. **The Board has approved an Interim Dividend of Rs. 0.40/- per equity share** (face value Rs 2 each) **aggregating to Rs. 4.58 Crores.** The record date to determine the names of members eligible for receipt of an interim dividend will be February 18, 2025 and the dividend will be paid on or before March 14, 2025.

Highlights of Consolidated Business & Standalone business

A) Nine Months Results:

a) Standalone Business Nine Months FY2024-2025 (Y-o-Y Basis)

1. Total revenue for the nine months has **increased to ~ Rs. 35,111 Lakhs from ~Rs. 31,936 Lakhs** i.e., a **growth of 9.94 %**.
2. Operational EBITDA for the nine months is at **25.82 %**.

b) Consolidated Nine Months FY 2023-2024 (Y-o-Y Basis)

1. Total revenue for the nine months has **increased to ~ Rs. 43,031 Lakhs from ~Rs. 42,834 Lakhs** i.e., a **growth of 0.46 %**.
2. Operational EBITDA for the nine months is at **25.62 %**.

B) Quarterly Results:

a) Standalone Business Quarter Q3-FY 2024-2025 (Y-o-Y Basis)

1. Total revenue for the quarter has **increased to ~ Rs. 11,384 Lakhs from ~Rs. 11,216 Lakhs** i.e., a **growth of 1.50 %**.
2. Operational EBITDA for the quarter is at **27.11 %**.

b) Consolidated Quarter Q3-FY 2024-2025 (Y-o-Y Basis)

1. Total revenue for the quarter has **decreased to ~ Rs. 13,091 Lakhs from ~Rs. 14,339 Lakhs**.
2. Operational EBITDA for the quarter is at **%.27.23 %**.

FINEOTEX®

A Speciality Chemical Producing
Public Listed Company



Kindly take the same on your records and oblige.

Thanking you,

Yours faithfully,

For FINEOTEX CHEMICAL LIMITED



Sanjay Tibrewala

Executive Director and CFO

DIN: 00218525

Encl: As above



FINEOTEX CHEMICAL LIMITED

Manorama Chambers, S.V. Road, Bandra (W), Mumbai - 400050. India. Phone: +91 - 22 2655 9174

Fax: +91-22 2655 9178 E-mail: info@fineotex.com Web: www.fineotex.com CIN - L24100MH200PLC144295



Independent Auditor's Review Report on the Standalone Unaudited Quarter and Nine months ended December 31,2024 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review Report to
The Board of Directors
Fineotex Chemical Limited**

1. We have reviewed the accompanying statement of Standalone Unaudited financial results (the "Statement") of Fineotex Chemical Limited (the "Company") for the quarter and nine months ended December 31, 2024, (the "Statement") attached herewith, being submitted by the Company pursuant to .the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Fineotex Chemical Limited**Independent Auditor's Review Report on the Unaudited Standalone Quarter and Nine months ended December 31,2024 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 specified under Section 133 of Act as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ASL & Co.
Chartered Accountants
(Regn No. 101921W)



(Shikha Jain)

Partner

Membership No.: 136484

UDIN: 25136484BMJMTW9263

Place: Mumbai

Date: February 12, 2025



FINEOTEX CHEMICAL LIMITED

(Company Identification Number :L24100MH2004PLC144295)

Regd. Off.:42/43, Manorama Chambers, S V Road, Bandra (W), Mumbai 400050

Telephone 022-26559174-77, Fax-022-22659178, email : Info@fineotex.com, Website : www.fineotex.com

(₹ In lakhs)

| STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2024 | | | | | | |
|---|------------------|------------------|------------------|-------------------|------------------|------------------|
| PARTICULARS | Quarter ended | | | Nine months ended | | Year Ended |
| | 31-Dec-24 | 30-Sep-24 | 31-Dec-23 | 31-Dec-24 | 31-Dec-23 | 31-Mar-24 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1 Income | | | | | | |
| a) Revenue from operation | 10,930.70 | 11,535.97 | 10,792.86 | 33,127.61 | 30,045.85 | 41,892.82 |
| b) Other Income | 453.25 | 1,106.17 | 423.10 | 1,983.45 | 1,890.61 | 3,242.37 |
| Total Income | 11,383.95 | 12,642.14 | 11,215.96 | 35,111.06 | 31,936.46 | 45,135.19 |
| 2 Expenses | | | | | | |
| a) Cost of materials consumed | 7,344.44 | 7,056.88 | 6,437.80 | 21,040.95 | 17,928.43 | 25,318.72 |
| b) Purchase of stock – in – trade | - | 131.12 | - | 131.12 | - | - |
| c) Changes in inventories of finished goods, work- in – process and stock – in – trade | (801.90) | (73.63) | (349.86) | (1,030.11) | (262.80) | (338.45) |
| d) Employee benefits expense | 527.23 | 528.20 | 472.54 | 1,542.08 | 1,349.37 | 1,823.17 |
| e) Finance costs | 16.59 | 10.51 | 19.86 | 37.68 | 47.68 | 81.10 |
| f) Depreciation and amortization expense | 188.64 | 173.62 | 114.45 | 529.67 | 332.61 | 452.48 |
| g) Other expenses | 897.51 | 922.72 | 779.98 | 2,891.13 | 2,556.82 | 3,743.58 |
| Total expenses | 8,172.51 | 8,749.43 | 7,474.77 | 25,142.52 | 21,952.11 | 31,080.60 |
| 3 Profit / (Loss) before tax (1-2) | 3,211.44 | 3,892.70 | 3,741.19 | 9,968.54 | 9,984.35 | 14,054.59 |
| 4 Tax expenses | | | | | | |
| a. Direct Tax | 695.00 | 688.22 | 918.00 | 2,038.16 | 2,147.04 | 2,850.64 |
| b. Indirect Tax | 67.62 | 59.42 | 49.72 | 151.76 | 608.29 | 141.29 |
| 5 Profit / (Loss) after tax (3-4) | 2,448.82 | 3,145.06 | 2,773.47 | 7,778.62 | 7,773.49 | 11,062.66 |
| 6 Other Comprehensive Income (OCI) (net of tax) | (5.71) | (1.97) | 0.17 | (17.14) | 0.49 | (23.62) |
| 7 Total Comprehensive Income for the period (5+6) | 2,443.11 | 3,143.09 | 2,773.64 | 7,761.48 | 7,773.98 | 11,039.04 |
| 8 Paid-up Equity share capital (Face Value ₹ 2/- each) | 2,318.71 | 2,318.21 | 2,215.30 | 2,318.71 | 2,215.30 | 2,215.30 |
| 9 Other Equity (Excluding Revaluation Reserve if any) | | | | | | 33,598.57 |
| 10 Earnings per Share (of ₹ 2/- each) (for Quarter and period ended not annualised): | | | | | | |
| a) Basic & Diluted EPS (₹/Share) | 2.16 | 2.77 | 2.50 | 6.85 | 7.02 | 9.99 |



Notes:

- 1 The above results were reviewed and recommended by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 2025. above results. The above results h
- 2 This Statement is as per F
- 3 These financial results together with the results of previous period have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 4 The Company mainly operates in a single primary business segment of Speciality Chemicals, therefore disclosure requirements as per Ind AS 108, "Operating Segments" are not applicable to the Company.

5 Issue of Equity Shares and Convertible Warrants , on preferential basis :

A During the earlier periods under review , the company had issued and allotted, Equity Shares and Convertible Warrants , on preferential basis , as detailed herein below :

Phase I - 22-05-2024

| | No. Of shares | Face Value (In Rs.) | Issue Price (In Rs.) | Total Consideration Received (Rs. In Lakhs) |
|---|---------------|-------------------------|-------------------------|--|
| Equity Shares | 9,70,000.00 | 2 | 346.00 | 3,356.20 |
| Convertible warrants - Partly Paid | 26,26,600.00 | 2 | 346.00 | 2,272.01 |
| Received During the Quarter Ended 30th June 2024 | | | | 5,628.21 |

Each Warrant is convertible into 1 fully paid-up equity share of Rs. issue price of Rs.

346/- ca

Phase II - 19-07-2024

| | No. Of shares | Face Value (In Rs.) | Issue Price (In Rs.) | Total Consideration Received (Rs. In Lakhs) |
|--|---------------|-------------------------|-------------------------|--|
| Equity Shares | 28,15,049.00 | 2 | 387.40 | 10,905.50 |
| Convertible warrants - Partly Paid | 28,15,049.00 | 2 | 387.40 | 2,726.37 |
| Received During the Quarter Ended 30th Sept. 2024 | | | | 13,631.87 |

Each Warrant is convertible into 1 fully paid-up equity share of Rs. the issue price of Rs.

387

- B The expenses incurred in respect of the above mentioned issue of Equity Shares and Convertible Warrants , on preferential basis of Rs. 983.75/- securities premium.
- 6 The Board of directors at its meetings today announced an Interim Dividend of Rs.0.40 determine the shareholders who will be entitled to received the dividend.
- 7 The Company allotted 25,052 equity shares of Rs.2/ FCL ESOP 2020 Scheme. up value of partly paid share warrants issued has detailed in Note no.5
- 8 EPS and Diluted EPS have been calculated after considering the equity shares issued and allotted during the period under review.
- 9 Previous periods figure have been regrouped, rearranged, reclassified wherever necessary to correspond with those of the current period.
- 10 The Notes on the above results were approved at the meeting of the Board of Directors of the Company held on 12th February , 2025.



For and on behalf of Board of Directors

Surendra Tibrewala
Surendra Tibrewala
Chairman & Managing Director
DIN 00218394

Aarti Jhunjunwala

Aarti Jhunjunwala
Executive Director
DIN: 07759722

Place: Mumbai
Date: 12th February , 2025.

Independent Auditor's Review Report on the Consolidated Unaudited Quarter and Nine months ended December 31,2024 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review Report to
The Board of Directors
Fineotex Chemical Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited financial results of Fineotex Chemical Limited (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting "prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.



Fineotex Chemical Limited

Independent Auditor's Review Report on the Consolidated Unaudited Quarter and Nine months ended December 31,2024 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

4. The Statement includes the results of the following entities:

| Name of Entity | Relationship |
|---|--|
| 1. Manya Manufacturing India Private Limited (Formerly Known as Manya Steels Private Limited) | Wholly Owned Subsidiary |
| 2. Fineotex Biotex Healthguard FZE (Formerly Known as Fineotex Specialities FZE) | Wholly Owned Subsidiary |
| 3. Fineotex Malaysia Limited | Wholly Owned Subsidiary |
| 4. FSPL Specialities Private Limited (Formerly Known as Fineotex Specialities Private Limited) | Wholly Owned Subsidiary Wholly Owned Subsidiary |
| 5. Finoclean Specialities Private Limited | Wholly Owned Subsidiary |
| Subsidiaries of Fineotex Malaysia Limited | |
| 6. BT Chemicals SDN.BHD. | Subsidiary |
| 7. BT Biotex SDN.BHD. | Subsidiary |
| 8. Rovatex SDN. BHD. | Subsidiary |
| 9. BT. Biotex Limited | Wholly Owned Subsidiary |

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the unreviewed and unaudited interim financial information prepared and furnished to us by the management and approved by the Board of Directors of the Parent Company referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial information of (9) Nine subsidiaries which have not been reviewed and are not audited, whose interim financial information reflects (before eliminating intercompany transactions) total revenues of ₹ 1,706.60 Lakhs and ₹ 7,919.77 Lakhs for the quarter and nine months ended December 31, 2024 respectively, total net profit/ (loss) after tax of ₹ 334.35 Lakhs and ₹ 1,129.08 Lakhs, for the quarter and nine months ended December 31, 2024 respectively. These interim financial information are not reviewed and are unaudited and have been prepared and furnished to us by the management of the Parent Company and in our opinion on the unaudited consolidated financial results, in so far as it relates to the amounts included in the consolidated unaudited financial results in respect of these subsidiary companies, is based solely on such unreviewed and unaudited interim financial



Fineotex Chemical Limited**Independent Auditor's Review Report on the Consolidated Unaudited Quarter and Nine months ended December 31,2024 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

information prepared and furnished to us by the management of the Parent Company and approved by the Board of Directors of the Parent Company.

Our Conclusion on the Statement is not modified in respect of our reliance on the unreviewed and unaudited interim financial information of these subsidiary companies certified by the Management of the Parent Company and approved by the Board of Directors of the Parent Company.

For ASL & Co.
Chartered Accountants
(Regn No. 101921W)



(Shikha Jain)

Partner

Membership No.: 136484

UDIN: 25136484BMJMTX6395



Place: Mumbai

Date: February 12, 2025

FINEOTEX CHEMICAL LIMITED

(Company Identification Number :L24100MH2004PLC144295)

Regd. Off.:42/43, Manorama Chambers, S V Road, Bandra (W), Mumbai 400050

Telephone 022-26559174-77, Fax-022-22659178, email : Info@fineotex.com, Website : www.fineotex.com

(₹ In lakhs)

| STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024 | | | | | | |
|---|------------------|------------------|------------------|-------------------|------------------|------------------|
| PARTICULARS | Quarter ended | | | Nine months ended | | Year Ended |
| | 31-Dec-24 | 30-Sep-24 | 31-Dec-23 | 31-Dec-24 | 31-Dec-23 | 31-Mar-24 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1 Income | | | | | | |
| a) Revenue from operation | 12,591.95 | 14,572.73 | 13,845.18 | 41,354.74 | 41,595.31 | 56,897.03 |
| b) Other Income | 498.60 | 689.98 | 493.52 | 1,676.08 | 1,239.14 | 1,653.75 |
| Total Income | 13,090.55 | 15,262.71 | 14,338.70 | 43,030.82 | 42,834.45 | 58,550.78 |
| 2 Expenses | | | | | | |
| a) Cost of materials consumed | 7,930.24 | 8,302.31 | 7,892.06 | 25,531.61 | 24,442.76 | 34,002.76 |
| b) Purchase of stock – in – trade | 196.66 | 504.42 | 313.09 | 734.00 | 1,089.76 | 1,412.98 |
| c) Changes in inventories of finished goods, work- in – process and stock – in – trade | (721.93) | 195.65 | (101.53) | (1,143.29) | (172.52) | (534.53) |
| d) Employee benefits expense | 605.66 | 611.26 | 545.07 | 1,777.01 | 1,562.21 | 2,116.47 |
| e) Finance costs | 20.45 | 21.51 | 29.47 | 66.58 | 74.65 | 133.14 |
| f) Depreciation and amortization expense | 258.95 | 237.20 | 143.06 | 721.02 | 416.99 | 602.04 |
| g) Other expenses | 1,152.03 | 1,319.88 | 1,161.26 | 3,861.54 | 3,663.97 | 5,061.22 |
| Total expenses | 9,442.06 | 11,192.23 | 9,982.48 | 31,548.47 | 31,077.82 | 42,794.08 |
| 3 Profit / (Loss) before tax (1-2) | 3,648.49 | 4,070.49 | 4,356.22 | 11,482.35 | 11,756.63 | 15,756.70 |
| 4 Tax expenses | | | | | | |
| a. Current Tax | 788.13 | 805.45 | 1,034.75 | 2,407.62 | 2,620.28 | 3,478.58 |
| b. Deferred Tax | 77.19 | 58.22 | 28.96 | 167.04 | 81.41 | 175.65 |
| 5 Profit / (Loss) after tax (3-4) | 2,783.17 | 3,206.81 | 3,292.51 | 8,907.69 | 9,054.94 | 12,102.47 |
| Attributable to: | | | | | | |
| (a) Owners of the Company | 2,763.45 | 3,185.35 | 3,267.13 | 8,823.89 | 8,970.20 | 11,980.84 |
| (b) Non-Controlling Interest | 19.72 | 21.47 | 25.38 | 83.80 | 84.74 | 121.63 |
| 6 Other Comprehensive Income (OCI) (net of tax) | (5.71) | (1.97) | 0.17 | (17.14) | 0.49 | (23.62) |
| 7 Total Comprehensive Income for the period (5+6) | 2,777.45 | 3,204.84 | 3,292.68 | 8,890.55 | 9,055.43 | 12,078.85 |
| Attributable to: | | | | | | |
| (a) Owners of the Company | 2,757.74 | 3,183.38 | 3,267.30 | 8,806.75 | 8,970.69 | 11,957.22 |
| (b) Non-Controlling Interest | 19.72 | 21.47 | 25.38 | 83.80 | 84.74 | 121.63 |
| 8 Paid-up Equity share capital (Face Value ₹ 2/- each) | 2,318.71 | 2,318.21 | 2,215.30 | 2,318.71 | 2,215.30 | 2,215.30 |
| 9 Other Equity (Excluding Revaluation Reserve if any) | | | | | | 42,493.92 |
| 10 Earnings per Share (of ₹ 2/- each) (for Quarter and period ended not annualised): | | | | | | |
| a) Basic & Diluted EPS (₹/Share) | 2.43 | 2.80 | 2.95 | 7.77 | 8.10 | 10.82 |



Notes:

- 1 The above consolidated results were reviewed and recommended by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 12th February, 2025. The above results have been subjected to Limited Review by the Statutory Auditors of the Company. The Statutory Auditors have expressed an unqualified report on the above results.
- 2 This Statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 3 These financial results together with the results of previous period have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 4 The Company mainly operates in a single primary business segment of Speciality Chemicals, therefore disclosure requirements as per Ind AS 108, "Operating Segments" are not applicable to the Company.

5 Issue of Equity Shares and Convertible Warrants , on preferential basis :

- A During the earlier periods under review , the company had issued and allotted, Equity Shares and Convertible Warrants , on preferential basis , as detailed herein below :

Phase I - 22-05-2024

| | No. Of shares | Face Value In Rs.) | (Issue Price (In Rs.) | Total Consideration Received (Rs. In Lakhs) |
|---|---------------|-----------------------|---------------------------|--|
| Equity Shares | 9,70,000.00 | 2 | 346.00 | 3,356.20 |
| Convertible warrants - Partly Paid | 26,26,600.00 | 2 | 346.00 | 2,272.01 |
| Received During the Quarter Ended 30th June 2024 | | | | 5,628.21 |

Each Warrant is convertible into 1 fully paid-up equity share of Rs. 2 each at Rs. 346/- each (including premium of Rs. 344/- each) in 18 months , subject to full payment of the issue price of Rs. 346/- each.

Phase II - 19-07-2024

| | No. Of shares | Face Value In Rs.) | (Issue Price (In Rs.) | Total Consideration Received (Rs. In Lakhs) |
|--|---------------|-----------------------|---------------------------|--|
| Equity Shares | 28,15,049.00 | 2 | 387.40 | 10,905.50 |
| Convertible warrants - Partly Paid | 28,15,049.00 | 2 | 387.40 | 2,726.37 |
| Received During the Quarter Ended 30th Sept. 2024 | | | | 13,631.87 |

Each Warrant is convertible into 1 fully paid-up equity share of Rs. 2 each at Rs. 387.40/- each (including premium of Rs. 385.40/- each) in 18 months , subject to full payment of the issue price of Rs. 387.40/- each.

- B The expenses incurred in respect of the above mentioned issue of Equity Shares and Convertible Warrants , on preferential basis of Rs. 983.75/- lakhs has been adjusted against securities premium.

- 6 The Board of directors at its meetings today announced an Interim Dividend of Rs.0.40 per share of Rs.2/- each (i.e.20%) and fixed determine the shareholders who will be entitled to received the dividend.
- 7 The Company allotted 25,052 equity shares of Rs.2/-each on this 13th November, 2024 to the eligible employee as approved by the Nomination Committee of the company as per FCL ESOP 2020 Scheme. Consequently, the issue and paid-up share capital of the company stands increased to Rs.2,318.71 Lakhs as on 31st December ,2024. (Including the paid up value of partly paid share warrants issued has detailed in Note no.5 above)
- 8 EPS and Diluted EPS have been calculated after considering the equity shares issued and allotted during the period under review.
- 9 Previous periods figure have been regrouped, rearranged, reclassified wherever necessary to correspond with those of the current period.
- 10 The Notes on the above results were approved at the meeting of the Board of Directors of the Company held on 12th February , 2025.

For and on behalf of Board of Directors

S. Tibrewala
Surendra Tibrewala
Chairman & Managing Director
DIN 00218394

A. Jhunjhunwala
Aarti Jhunjhunwala
Executive Director
DIN: 07759722

Place: Mumbai
Date: 12th February , 2025.

